The popular hepatitis C drug telaprevir (Incivek) could be linked with a potentially deadly skin disease, says the drug's manufacturer Vertex Pharmaceuticals. The company made the announcement this week and says that they will soon include a warning label on the drug.
"Fatal cases of serious skin reactions have been reported in patients with progressive rash and systemic symptoms who continued to receive Incivek combination treatment after a serious skin reaction was identified," Vertex confirmed in their statement.
The company says that anyone experiencing severe skin rashes while taking the drug should suspend use immediately. Though severe rashes were seen during its FDA trials, reports of death did not arise until after the drug's postmarketing phase.
"Given the severity of the events reported in the postmarketing setting, and the importance of discontinuing Incivek combination treatment in the event of one of these reactions, the information has been given greater prominence through a boxed warning," Vertex adds.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.